Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse

References

• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med 2008; 59:237 - 50; http://dx.doi.org/10.1146/annurev.med.59.060906.220345; PMID: 18186705
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, et al, International Group of Investigators, German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164 - 74; http://dx.doi.org/10.1016/S0140-6736(10)61381-5; PMID: 20888994
   PubMed Web of Science ®Google Scholar
• Ruuls SR, Lammerts van Bueren JJ, van de Winkel JGJ, Parren PWHI. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3:1157 - 71; http://dx.doi.org/10.1002/biot.200800110; PMID: 18702090
   PubMedGoogle Scholar
• Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood 2004; 104:2635 - 42; http://dx.doi.org/10.1182/blood-2004-03-1110; PMID: 15226177
   PubMed Web of Science ®Google Scholar
• Boross P, Leusen JHW. Mechanisms of action of CD20 antibodies. Am J Cancer Res 2012; 2:676 - 90; PMID: 23226614
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-López AJ, White CA, McLaughlin P, Czuczman MS, Link BK, Maloney DG, Weaver RL, Rosenberg J, Levy R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J ClinOncol 2000; 18:3135 - 43; PMID: 10963642
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22:7359 - 68; http://dx.doi.org/10.1038/sj.onc.1206939; PMID: 14576843
   PubMed Web of Science ®Google Scholar
• Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J BiolChem 2003; 278:3466 - 73; http://dx.doi.org/10.1074/jbc.M210665200; PMID: 12427744
   PubMed Web of Science ®Google Scholar
• Moore GL, Chen H, Karki S, Lazar GA. Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs 2010; 2:181 - 9; http://dx.doi.org/10.4161/mabs.2.2.11158; PMID: 20150767
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin’s lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res 2003; 9:5866 - 73; PMID: 14676108
   PubMed Web of Science ®Google Scholar
• Gluck WL, Hurst D, Yuen A, Levine AM, Dayton MA, Gockerman JP, Lucas J, Denis-Mize K, Tong B, Navis D, et al. Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin’s lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response. Clin Cancer Res 2004; 10:2253 - 64; http://dx.doi.org/10.1158/1078-0432.CCR-1087-3; PMID: 15073100
   PubMed Web of Science ®Google Scholar
• Eisenbeis CF, Grainger A, Fischer B, Baiocchi RA, Carrodeguas L, Roychowdhury S, Chen L, Banks AL, Davis T, Young D, et al. Combination immunotherapy of B-cell non-Hodgkin’s lymphoma with rituximab and interleukin-2: a preclinical and phase I study. Clin Cancer Res 2004; 10:6101 - 10; http://dx.doi.org/10.1158/1078-0432.CCR-04-0525; PMID: 15447996
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Williams S, Carr F, Forman S, Raubitschek A, Lo K-M. An anti-CD20-IL-2 immunocytokine is highly efficacious in a SCID mouse model of established human B lymphoma. Blood 2005; 105:3972 - 8; http://dx.doi.org/10.1182/blood-2004-09-3533; PMID: 15692062
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Antibody-cytokine fusion proteins. Arch BiochemBiophys 2012; 526:194 - 205; http://dx.doi.org/10.1016/j.abb.2012.03.001; PMID: 22445675
   PubMed Web of Science ®Google Scholar
• Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583 - 90; http://dx.doi.org/10.1016/j.drudis.2012.01.007; PMID: 22289353
   PubMed Web of Science ®Google Scholar
• Munger W, DeJoy SQ, Jeyaseelan R Sr., Torley LW, Grabstein KH, Eisenmann J, Paxton R, Cox T, Wick MM, Kerwar SS. Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 1995; 165:289 - 93; http://dx.doi.org/10.1006/cimm.1995.1216; PMID: 7553894
   PubMed Web of Science ®Google Scholar
• Anderson DM, Kumaki S, Ahdieh M, Bertles J, Tometsko M, Loomis A, Giri J, Copeland NG, Gilbert DJ, Jenkins NA, et al. Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes. J BiolChem 1995; 270:29862 - 9; http://dx.doi.org/10.1074/jbc.270.50.29862; PMID: 8530383
   PubMed Web of Science ®Google Scholar
• Giri JG, Kumaki S, Ahdieh M, Friend DJ, Loomis A, Shanebeck K, DuBose R, Cosman D, Park LS, Anderson DM. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J 1995; 14:3654 - 63; PMID: 7641685
   PubMed Web of Science ®Google Scholar
• Dubois S, Mariner J, Waldmann TA, Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002; 17:537 - 47; http://dx.doi.org/10.1016/S1074-7613(02)00429-6; PMID: 12433361
   PubMed Web of Science ®Google Scholar
• Burkett PR, Koka R, Chien M, Chai S, Boone DL, Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J Exp Med 2004; 200:825 - 34; http://dx.doi.org/10.1084/jem.20041389; PMID: 15452177
   PubMed Web of Science ®Google Scholar
• Mortier E, Advincula R, Kim L, Chmura S, Barrera J, Reizis B, Malynn BA, Ma A. Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets. Immunity 2009; 31:811 - 22; http://dx.doi.org/10.1016/j.immuni.2009.09.017; PMID: 19913445
   PubMed Web of Science ®Google Scholar
• Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, Matsuki N, Charrier K, Sedger L, Willis CR, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771 - 80; http://dx.doi.org/10.1084/jem.191.5.771; PMID: 10704459
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595 - 601; http://dx.doi.org/10.1038/nri1901; PMID: 16868550
   PubMed Web of Science ®Google Scholar
• Marks-Konczalik J, Dubois S, Losi JM, Sabzevari H, Yamada N, Feigenbaum L, Waldmann TA, Tagaya Y. IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. ProcNatlAcadSci U S A 2000; 97:11445 - 50; http://dx.doi.org/10.1073/pnas.200363097; PMID: 11016962
   PubMed Web of Science ®Google Scholar
• Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9:480 - 90; http://dx.doi.org/10.1038/nri2580; PMID: 19543225
   PubMed Web of Science ®Google Scholar
• Moga E, Alvarez E, Cantó E, Vidal S, Rodríguez-Sánchez JL, Sierra J, Briones J. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. ExpHematol 2008; 36:69 - 77; http://dx.doi.org/10.1016/j.exphem.2007.08.012; PMID: 17959301
   PubMed Web of Science ®Google Scholar
• Moga E, Cantó E, Vidal S, Juarez C, Sierra J, Briones J. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. ExpHematol 2011; 39:1064 - 71; http://dx.doi.org/10.1016/j.exphem.2011.08.006; PMID: 21864486
   PubMed Web of Science ®Google Scholar
• Laprevotte E, Voisin G, Ysebaert L, Klein C, Daugrois C, Laurent G, Fournie J-J, Quillet-Mary A. Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy. J Immunol 2013; 191:3634 - 40; http://dx.doi.org/10.4049/jimmunol.1300187; PMID: 23997218
   PubMed Web of Science ®Google Scholar
• Mortier E, Bernard J, Plet A, Jacques Y. Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol 2004; 173:1681 - 8; PMID: 15265897
   PubMed Web of Science ®Google Scholar
• Dubois S, Patel HJ, Zhang M, Waldmann TA, Müller JR. Preassociation of IL-15 with IL-15R alpha-IgG1-Fc enhances its activity on proliferation of NK and CD8+/CD44high T cells and its antitumor action. J Immunol 2008; 180:2099 - 106; PMID: 18250415
   PubMed Web of Science ®Google Scholar
• Epardaud M, Elpek KG, Rubinstein MP, Yonekura AR, Bellemare-Pelletier A, Bronson R, Hamerman JA, Goldrath AW, Turley SJ. Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res 2008; 68:2972 - 83; http://dx.doi.org/10.1158/0008-5472.CAN-08-0045; PMID: 18413767
   PubMed Web of Science ®Google Scholar
• Stoklasek TA, Schluns KS, Lefrançois L. Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol 2006; 177:6072 - 80; PMID: 17056533
   PubMed Web of Science ®Google Scholar
• Mortier E, Quéméner A, Vusio P, Lorenzen I, Boublik Y, Grötzinger J, Plet A, Jacques Y. Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J BiolChem 2006; 281:1612 - 9; http://dx.doi.org/10.1074/jbc.M508624200; PMID: 16284400
   PubMed Web of Science ®Google Scholar
• Bouchaud G, Garrigue-Antar L, Solé V, Quéméner A, Boublik Y, Mortier E, Perdreau H, Jacques Y, Plet A. The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J MolBiol 2008; 382:1 - 12; http://dx.doi.org/10.1016/j.jmb.2008.07.019; PMID: 18656487
   PubMed Web of Science ®Google Scholar
• Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H, et al. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med 2009; 206:25 - 34; http://dx.doi.org/10.1084/jem.20082013; PMID: 19103877
   PubMed Web of Science ®Google Scholar
• Bessard A, Solé V, Bouchaud G, Quéméner A, Jacques Y. High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther 2009; 8:2736 - 45; http://dx.doi.org/10.1158/1535-7163.MCT-09-0275; PMID: 19723883
   PubMed Web of Science ®Google Scholar
• Vincent M, Bessard A, Cochonneau D, Teppaz G, Solé V, Maillasson M, Birklé S, Garrigue-Antar L, Quéméner A, Jacques Y. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer 2013; 133:757 - 65; http://dx.doi.org/10.1002/ijc.28059; PMID: 23354868
   PubMed Web of Science ®Google Scholar
• Clémenceau B, Vivien R, Pellat C, Foss M, Thibault G, Vié H. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential. MAbs 2013; 5:587 - 94; http://dx.doi.org/10.4161/mabs.25077; PMID: 23770975
   PubMed Web of Science ®Google Scholar
• Perdreau H, Mortier E, Bouchaud G, Solé V, Boublik Y, Plet A, Jacques Y. Different dynamics of IL-15R activation following IL-15 cis- or trans-presentation. Eur Cytokine Netw 2010; 21:297 - 307; PMID: 21078585
   PubMed Web of Science ®Google Scholar
• Blasco H, Lalmanach G, Godat E, Maurel MC, Canepa S, Belghazi M, Paintaud G, Degenne D, Chatelut E, Cartron G, et al. Evaluation of a peptide ELISA for the detection of rituximab in serum. J Immunol Methods 2007; 325:127 - 39; http://dx.doi.org/10.1016/j.jim.2007.06.011; PMID: 17651747
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803 - 43; http://dx.doi.org/10.2165/00003495-200363080-00005; PMID: 12662126
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J ClinOncol 1998; 16:2825 - 33; PMID: 9704735
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443 - 6; http://dx.doi.org/10.1038/74704; PMID: 10742152
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lan Y, Lo KM, Super M, Wesolowski J. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors. Cancer Res 1999; 59:2159 - 66; PMID: 10232603
   PubMed Web of Science ®Google Scholar
• Gillies SD, Lo K-M, Burger C, Lan Y, Dahl T, Wong W-K. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin Cancer Res 2002; 8:210 - 6; PMID: 11801561
   PubMed Web of Science ®Google Scholar
• Kendra K, Gan J, Ricci M, Surfus J, Shaker A, Super M, Frost JD, Rakhmilevich A, Hank JA, Gillies SD, et al. Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice. Cancer ImmunolImmunother 1999; 48:219 - 29; http://dx.doi.org/10.1007/s002620050569; PMID: 10478638
   PubMedGoogle Scholar
• Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 2012; 119:5640 - 9; http://dx.doi.org/10.1182/blood-2012-01-380121; PMID: 22535666
   PubMed Web of Science ®Google Scholar
• Eisenman J, Ahdieh M, Beers C, Brasel K, Kennedy MK, Le T, Bonnert TP, Paxton RJ, Park LS. Interleukin-15 interactions with interleukin-15 receptor complexes: characterization and species specificity. Cytokine 2002; 20:121 - 9; http://dx.doi.org/10.1006/cyto.2002.1989; PMID: 12453470
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res ClinHaematol 2011; 24:203 - 16; http://dx.doi.org/10.1016/j.beha.2011.02.009; PMID: 21658619
   PubMed Web of Science ®Google Scholar
• Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006; 176:2600 - 9; PMID: 16456022
   PubMed Web of Science ®Google Scholar
• Hori T, Uchiyama T, Tsudo M, Umadome H, Ohno H, Fukuhara S, Kita K, Uchino H. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987; 70:1069 - 72; PMID: 3115332
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Russell SM, Mess SA, Friedmann M, Erdos M, Francois C, Jacques Y, Adelstein S, Leonard WJ. Heterodimerization of the IL-2 receptor beta- and gamma-chain cytoplasmic domains is required for signalling. Nature 1994; 369:330 - 3; http://dx.doi.org/10.1038/369330a0; PMID: 8183373
   PubMed Web of Science ®Google Scholar
• Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, Watier H, Thibault G. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res 2004; 64:4664 - 9; http://dx.doi.org/10.1158/0008-5472.CAN-03-2862; PMID: 15231679
   PubMed Web of Science ®Google Scholar
• Congy-Jolivet N, Bolzec A, Ternant D, Ohresser M, Watier H, Thibault G. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res 2008; 68:976 - 80; http://dx.doi.org/10.1158/0008-5472.CAN-07-6523; PMID: 18281470
   PubMed Web of Science ®Google Scholar
• Wu L, Wang C, Zhang D, Zhang X, Qian W, Zhao L, Wang H, Li B, Guo Y. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma. Cancer Lett 2010; 292:208 - 14; http://dx.doi.org/10.1016/j.canlet.2009.12.004; PMID: 20056316
   PubMed Web of Science ®Google Scholar